These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 14619248)

  • 21. Global cost-effectiveness of cataract surgery.
    Lansingh VC; Carter MJ; Martens M
    Ophthalmology; 2007 Sep; 114(9):1670-8. PubMed ID: 17383730
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation.
    Briggs AH; Wonderling DE; Mooney CZ
    Health Econ; 1997; 6(4):327-40. PubMed ID: 9285227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost effectiveness of telehealth for patients with long term conditions (Whole Systems Demonstrator telehealth questionnaire study): nested economic evaluation in a pragmatic, cluster randomised controlled trial.
    Henderson C; Knapp M; Fernández JL; Beecham J; Hirani SP; Cartwright M; Rixon L; Beynon M; Rogers A; Bower P; Doll H; Fitzpatrick R; Steventon A; Bardsley M; Hendy J; Newman SP;
    BMJ; 2013 Mar; 346():f1035. PubMed ID: 23520339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Squinting through layers of fog: assessing the cost effectiveness of treatments for multiple sclerosis.
    Hawton A; Shearer J; Goodwin E; Green C
    Appl Health Econ Health Policy; 2013 Aug; 11(4):331-41. PubMed ID: 23637055
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcome measurement in economic evaluation.
    Johannesson M; Jönsson B; Karlsson G
    Health Econ; 1996; 5(4):279-96. PubMed ID: 8880165
    [No Abstract]   [Full Text] [Related]  

  • 26. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention?
    Phillips KA; Hotlgrave DR
    Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost and outcomes analysis.
    King JT; Ratcheson RA
    Neurosurg Clin N Am; 1998 Jul; 9(3):629-40. PubMed ID: 9668193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
    Barbieri M; Drummond M; Willke R; Chancellor J; Jolain B; Towse A
    Value Health; 2005; 8(1):10-23. PubMed ID: 15841890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus.
    Roe RH; Lass JH; Brown GC; Brown MM
    Cornea; 2008 Oct; 27(9):1001-7. PubMed ID: 18812762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be?
    Birch S; Gafni A
    J Health Econ; 1992 Oct; 11(3):279-96. PubMed ID: 10122540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-benefit analyses in the health-care literature: don't judge a study by its label.
    Zarnke KB; Levine MA; O'Brien BJ
    J Clin Epidemiol; 1997 Jul; 50(7):813-22. PubMed ID: 9253393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economics notes: Converting international cost effectiveness data to UK prices.
    Gosden TB; Torgerson DJ
    BMJ; 2002 Aug; 325(7358):275-6. PubMed ID: 12153929
    [No Abstract]   [Full Text] [Related]  

  • 34. Editorial comment--stroke cost-effectiveness research: are acceptability curves acceptable?
    Holloway R; Dick AW
    Stroke; 2004 Jan; 35(1):203-4. PubMed ID: 14684768
    [No Abstract]   [Full Text] [Related]  

  • 35. Accounting for future costs in medical cost-effectiveness analysis.
    Meltzer D
    J Health Econ; 1997 Feb; 16(1):33-64. PubMed ID: 10167344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls.
    Bambha K; Kim WR
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):519-26. PubMed ID: 15167152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-utility and cost-benefit analyses: how did we get here and where are we going?
    Moayyedi P; Mason J
    Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):527-34. PubMed ID: 15167153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis in heart disease, Part I: General principles.
    Kupersmith J; Holmes-Rovner M; Hogan A; Rovner D; Gardiner J
    Prog Cardiovasc Dis; 1994; 37(3):161-84. PubMed ID: 7972851
    [No Abstract]   [Full Text] [Related]  

  • 39. The potential to forgo social welfare gains through overrelianceon cost effectiveness/cost utility analyses in the evidence base for public health.
    Cohen DR; Patel N
    J Environ Public Health; 2009; 2009():107927. PubMed ID: 20049165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How much are health-care systems prepared to pay to produce a QALY?
    Buxton MJ
    Eur J Health Econ; 2005 Dec; 6(4):285-7. PubMed ID: 16258748
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.